{
    "name": "gadobenate",
    "comment": "Rx",
    "other_names": [
        "MultiHance"
    ],
    "classes": [
        "Gadolinium-Containing Contrast Agents",
        "Contrast Media",
        "Nonionic/ High Osmolality"
    ],
    "source": "https://reference.medscape.com/drug/multihance-gadobenate-343765",
    "pregnancy": {
        "common": [
            "GBCAs cross the placenta and result in fetal exposure and gadolinium retention",
            "Human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive",
            "In animal reproduction studies, gadobenate has been shown to be teratogenic in rabbits following repeated IV administration during organogenesis at doses up to 6 times the recommended human dose; no adverse developmental effects observed in rats with IV administration of gadobenate dimeglumine during organogenesis at doses up to 3 times the recommended human dose",
            "Estimated background risk of major birth defects and miscarriage for the indicated population is unknown",
            "All pregnancies have a background risk of birth defect, loss, or other adverse outcomes"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Limited literature reports that breastfeeding after gadobenate administration to the mother would result in the infant receiving an oral dose of 0.001%-0.04% of the maternal dose",
            "Unknown whether the effects of the drug on the breastfed infant or the effects of the drug on milk production",
            "Developmental and health benefits of breastfeeding should be considered together with the mother’s clinical need for gadobenate and any potential adverse effects on the breastfed infant from gadobenate or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Nephrogenic systemic fibrosis",
                    "description": [
                        "Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs",
                        "Avoid use of GBCAs in these patients unless diagnostic information is essential and not available with noncontrasted MRI or other modalities  NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs",
                        "Highest risk for NSF is among patients with chronic, severe kidney disease (GFR <30 mL/min/1.73²) or acute kidney injury",
                        "Screen patients for acute kidney injury and other conditions that may reduce renal function",
                        "For patients at risk for chronically reduced renal function (eg, age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing",
                        "For patients at highest risk for NSF, do not exceed recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity; known allergy to gadolinium or formulation components"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations; observe patients for signs and symptoms of a hypersensitivity reaction during and for up to 2 hr after administration (see Contraindications)",
                "Risk for nephrogenic systemic fibrosis (NSF) in patients w/ acute or chronic severe renal insufficiency, hepatorenal syndrome or in perioperative liver transplantation period (see Black Box Warnings)",
                "Anemia, hepatic/renal impairment, hemoglobinopathies, thrombotic syndromes",
                "Risk of hypotension/hypertension",
                "Patients with or using medication for metabolic, cardiac, or other abnormalities predisposing to cardiac arrhythmias",
                "Cardiac arrhythmias reported; use caution in patients with predisposing proarrhythmic conditions or that are taking proarrhythmic drug therapy concurrently",
                "May prolong systemic exposure in patients with decreased multispecific organic anion transporters",
                "Local tissue damage may occur in extravasation",
                "Certain lesions seen on non-contrast images may not be seen on contrast- images; exercise caution when interpreting contrast MR images in the absence of companion non-contrast MR images"
            ],
            "specific": [
                {
                    "type": "Gadolinium retention",
                    "description": [
                        "Gadolinium is retained for months or years in several organs",
                        "Highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (eg, brain, skin, kidney, liver, and spleen",
                        "Duration of retention also varies by tissue and is longest in bone",
                        "Patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions are at higher risk of gadolinium retention"
                    ]
                },
                {
                    "type": "Brain deposits",
                    "description": [
                        "FDA review to date has not identified adverse health effects from gadolinium retained in the brain after the use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI)",
                        "Restriction of GBCA use is not warranted because there is no evidence associated with gadolinium retention in the brain from any of the GBCAs, including GBCAs associated with higher retention of gadolinium",
                        "Recent publications in medical literature have reported that deposits of GBCAs remain in the brains of some patients who undergo ≥4 contrast MRI scans, long after the last administration",
                        "It is unknown whether these gadolinium deposits are harmful or can lead to adverse health effects",
                        "Early data in rat studies show that linear GBCAs are more prone to dissociation into free gadolinium and demonstrate greater brain deposition than macrocyclic GBCAs, which are less prone to dissociation",
                        "Health care professionals should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary, and assess the necessity of repetitive MRIs with GBCAs"
                    ]
                },
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Gadobenate may prolong systemic exposure of drugs such as cisplatin, anthracyclines (eg, doxorubicin, daunorubicin), vinca alkaloids (eg, vincristine), methotrexate, etoposide, tamoxifen, and paclitaxel",
                        "Consider the potential for prolonged drug exposure in patients with decreased canalicular multispecific organic anion transporter (MOAT also referred to as MRP2 or ABCC2) activity (eg, Dubin Johnson syndrome)"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "1.3"
        },
        {
            "name": "Headache",
            "percent": "1.2"
        },
        {
            "name": "Injection site reactions",
            "percent": "1.1"
        },
        {
            "name": "Feeling hot",
            "percent": "1"
        },
        {
            "name": "Dysgeusia",
            "percent": "0.7"
        },
        {
            "name": "Pyrexia",
            "percent": "0.7"
        },
        {
            "name": "pediatric patients",
            "percent": "0.7"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "0.5"
        },
        {
            "name": "pediatric patients",
            "percent": "0.5"
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactic",
            "percent": null
        },
        {
            "name": "anaphylactoid and hypersensitivity reactions manifested with various degrees of severity up to anaphylactic shock",
            "percent": null
        },
        {
            "name": "loss of consciousness and death",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Extravasation of the drug may lead to injection site reactions",
            "percent": null
        },
        {
            "name": "characterized by local pain or burning sensation",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "blistering",
            "percent": null
        },
        {
            "name": "and necrosis",
            "percent": null
        },
        {
            "name": "Gadolinium retention in patients with normal renal function",
            "percent": null
        },
        {
            "name": "adverse events",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "fatigue",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "pain syndromes",
            "percent": null
        },
        {
            "name": "and heterogeneous clusters of symptoms in the neurological",
            "percent": null
        },
        {
            "name": "cutaneous",
            "percent": null
        },
        {
            "name": "and musculoskeletal systems",
            "percent": null
        },
        {
            "name": "with variable onset and duration have been reported",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "Gadolinium",
            "percent": null
        },
        {
            "name": "associated plaques",
            "percent": null
        }
    ]
}